Abstract
The neurotrophic tyrosine kinase receptor 1-3 (NTRK 1-3) genes encode tropomyosin receptor kinases (TRK), TRKA, TRKB, and TRKC. Fusion translocations of NTRK genes are rare in a wide range of solid and hematological tumors in children and adults.
TRK inhibitors offer the possibility of selectively influencing this signaling pathway with a dramatic and longlasting effect. Larotrectinib and entrectinib are currently targeted therapeutic options for patients with a proven NTRK gene fusion in our country.